Abstract The outcome of Guillain-Barré syndrome (GBS) remains unchanged since plasma exchange and intravenous immunoglobulin (IVIg) were introduced over 20 years ago. Pathogenesis studies on GBS have identified the terminal component of complement cascade as a key disease mediator and therapeutic target. We report the first use of terminal complement pathway inhibition with eculizumab in humans with GBS. In a randomised, double-blind, placebo-controlled trial, 28 subjects eligible on the basis of GBS disability grade of at least 3 were screened, of whom 8 (29%) were randomised. Five received eculizumab for 4 weeks, alongside standard IVIg treatment. The safety outcomes, monitored via adverse events capture, showed eculizumab to be well-tolerated and safe when administered in conjunction with IVIg. Primary and secondary efficacy outcomes in the form of GBS disability scores (GBS DS), MRC sum scores, Rasch overall disability scores, and overall neuropathy limitation scores are reported descriptively. For the primary efficacy outcome at 4 weeks after recruitment, two of two placebo-and two of five eculizumab-treated subjects had improved by one or more grades on the GBS DS. Although the small sample size precludes a statistically meaningful analysis, these pilot data indicate further studies on complement inhibition in GBS are warranted.
Introduction
Over 20 years after their introduction, intravenous immunoglobulin (IVIg) and plasma exchange remain the only proven therapies for Guillain-Barré syndrome (GBS) (Hughes et al., 2014) . As the use of these interventions became routine in clinical practice, no further immunomodulatory therapies have been shown to significantly ameliorate the clinical course of GBS, whether used alone or in conjunction with IVIg (Hughes et al., 2013) .
IgG anti-ganglioside antibodies are strongly implicated in the pathogenesis of at least some forms of GBS Willison, 2005) by activating complement during the acute inflammatory phase. Human biopsies from GBS subjects reveal complement deposits in nerves (Griffin et al., 1996) . Data from animal models have demonstrated that inhibition of the terminal components of the complement cascade can abrogate nerve damage (van Schaik et al., 1995; Goodyear et al., 1999; Yuki et al., 2001; O'Hanlon et al., 2003; Halstead et al., 2008; Greenshields et al., 2009) thus making complement an attractive therapeutic target.
Eculizumab (Soliris™; Alexion Pharmaceuticals, New Haven, CT, USA) is currently the only commercially available complement C5 inhibitor approved for use in man. It is a humanised anti-C5 neutralising antibody which prevents the formation of membrane attack complex (MAC) (Rother et al., 2007) . In 2011, an open-label clinical trial of eculizumab in multifocal motor neuropathy (MMN) provided valuable data on serum eculizumab concentrations required to inhibit MAC formation in subjects receiving concomitant IVIg (Fitzpatrick et al., 2011) . We report here an exploratory study of eculizumab used as an add-on to IVIg in GBS.
Materials and Methods

Patients
Patients who fulfilled the National Institute of Neurological Disorders and Stroke criteria for diagnosis of GBS (Asbury and Cornblath, 1990) were included. Entry criteria required participants to be at least 18 years of age, within 2 weeks of GBS symptom onset, have a GBS disability score (GBS DS) of at least 3 (defined as inability to walk 10 m unaided), with no confounding medical conditions. Full inclusion and exclusion criteria are documented in Table 1 . Regional ethical approval was given for the trial protocol and supporting documentation (REC13/SS/0117). All trial conduct was in keeping with the Declaration of Helsinki. The trial is registered on EudraCT database (unique no. 2013-000228-33) and Clinicaltrials.gov (NCT02029378).
Study design
Inhibition of complement activation in GBS (ICA-GBS) was designed as a phase 2, single centre, 2 : 1 randomised, double-blind, placebo-controlled trial aiming to recruit 30 patients over a 2-year period (August 2014 to July 2016) with severe GBS. Randomisation and concealed allocation were performed by computer and an interactive web response system. In both arms, participants received IVIg at 2 g/kg (0.4 g/kg/day for 5 days). All participants were enrolled for a 6-month period, comprising eight visits, at weeks 0-4, 8, 13, and 26. Active drug (eculizumab, 900 mg) or placebo was given weekly (weeks 1-4) for the first 4 weeks. Concomitant antibiotics (Ciprofloxacin 400 mg oral/500 mg IV once weekly) were given to all participants for the first 10 weeks for meningococcal prophylaxis in the absence of an opportunity to vaccinate eculizumab recipients. When the first dose of study drug was administered, all participants were also receiving IVIg therapy (2 g/kg in five divided doses over 5 days) at various timepoints. Outcome data, as denoted in Table 2 , were collected throughout the trial and comprised GBS DS (Hughes et al., 1978) and Medical Research Council (MRC) sum score (MRC SS) (Kleyweg et al., 1991) and both collected weekly. The Rasch-built overall disability score (R-ODS) (van Nes et al., 2011) and overall neuropathy limitation score (ONLS) (Draak et al., 2014) were collected at baseline, weeks 4, 8, 13, and 26 visits (Table 2 ). For full descriptions of scales and scores, see Appendix 3A-D in the Supporting Information.
Study outcomes
The primary safety endpoint was the incidence of adverse events (AEs) and serious adverse events (SAEs) after treatment with eculizumab and IVIg compared with placebo controls who received IVIg only. Safety was recorded via AE and SAE reporting occurring during the treatment period and for unresolved SAEs the subsequent 6 months. The primary efficacy endpoint was defined as improvement by one or more grades in GBS DS at 4 weeks. The secondary endpoints are documented in Table 2 .
Electrophysiology
Routine clinical electrophysiological data were collected, with all subjects having a least one detailed study, recording from at least four nerve and muscle groups. These data were then analysed by one clinical neurophysiologist (A. M.) and compared with the Rajabally diagnostic criteria (Rajabally et al., 2015) .
Laboratory and pharmacological monitoring
Blood samples were taken prior to each eculizumab or placebo dose, and assays were performed at baseline for anti-ganglioside antibodies using enzyme-linked immunosorbent assay and microarray (Cao-Lormeau et al., 2016) .
Statistics
The study protocol specified that a statistical analysis plan (SAP) would be formulated prior to unblinding the trial. As the study only recruited 8 participants of the intended 30, it was agreed that there would be no value to estimate treatment effect difference, and the final SAP consisted of descriptive analyses only. alcoholism, severe vitamin deficiency, and porphyria. 4 Patient received immunosuppressive* treatment during the last month. 5 Patient known to have a severe concurrent disease, inability to comply with study-related procedures or appointments during 6 months. 6 Any condition that in the opinion of the investigator could increase the patient's risk by participating in the study or confound the outcome of the study. 7 Enrollment in another CTIMP 6 months prior to consent. 
Results
Subjects
There were an unexpectedly large number of exclusions of potentially eligible subjects at prescreening. Thus, of the 28 subjects with severe GBS over the 2-year study period who underwent pre-screening, 20 subjects failed to enter the trial for a number of reasons ( Fig. 1 , Appendix Table 1 in the Supporting Information). Of these 12 subjects declined to participate, the most common reason being concern about the perceived risks of meningitis and infection associated with the trial drug. Eight were excluded for other reasons including concomitant pyrexial illness, past history of meningococcal central nervous system (CNS) infection, and inability to comply with study schedules. Table 3 lists baseline clinical characteristics of recruited subjects.
Eight subjects were recruited and randomised. One randomised patient was withdrawn due to an exclusion criterion (incidental chest neoplasm identified on CT scanning) arising after consent was given, but before any baseline visit actions were undertaken. All seven remaining subjects received standard IVIg treatment at 0.4 g/kg/day for 5 days, with the first trial visit and dosing occurring during this time period. Of the seven who received trial infusions and completed the study, five received eculizumab (subjects E1-E5) and two received placebo (subjects P1 and P2). One patient (E3), who was gradually improving from their GBS disability over the course of the study, died suddenly of septic shock at week 21. All other subjects (n = 6) completed the predefined 26-week observation period and outcome measures.
All seven subjects who completed the trial had clinical features that were typical for GBS with largely symmetrical motor weakness, reflex loss, and elevated cerebrospinal fluid protein. Five subjects had associated anti-ganglioside antibodies (Table 3) . Electrophysiological studies (Appendix 4 in the Supporting Information) showed that amongst the eculizumab-treated subjects, two (E1 and E2) had Acute Motor Axonal Neuropathy (AMAN) or Acute Motor and Sensory Axonal Neuropathy 1. Ability to walk unaided (GBS DS ≤ 2) at 8 weeks 2. Time taken to improve in one grade on the GBS DS 3. Time taken to walk independently 4. Difference in GBS DS at maximum disability compared with 6 months 5. Percentage of participants with a clinically relevant improvement in R-ODS score defined as an increase from baseline in R-ODS score by at least 6 points on the centile metric score at 4 weeks and 6 months 6. Percentage of participants with a clinically relevant improvement in ONLS defined as a decrease from baseline in ONLS score by at least one point at 4 weeks and 6 months 7. Requirement for ventilatory support (GBS DS = 5) 8. Duration of ventilatory support 9. Recurrence of relapse 10. Death within first 6 months Baseline defined as week 0, or day 1 prior to drug administration. GBS, Guillain-Barré syndrome; GBS DS, GBS disability score; R-ODS, Rasch overall disability score; ONLS, overall neuropathy limitation score; IVIg, intravenous immunoglobulin.
(AMSAN) pattern and two had Acute Inflammatory Demyelinating Polyneuropathy (AIDP) patterns. One subject (E5) had equivocal studies. Both placebo patients had AIDP electrophysiological patterns.
Primary outcome -safety and tolerability
Administration of the first dose of study drug occurred at least 1 h post IVIg infusion. One patient reported a rash after the third dose of study drug; otherwise no infusion reactions were noted. Of the five who received eculizumab, two did not fully complete the four scheduled infusions. One patient (E3) received two of four intended doses (missing weekly dose 3 and 4) and the other patient (E4) received three of four (missing weekly dose 3). In both subjects, treatment was withheld because of active respiratory infection with pyrexia and sepsis as per protocol.
Adverse Events
AEs were captured for the duration of the trial (Table 4 and Appendix Table 2 in the Supporting Information). For all seven subjects who completed the full treatment phase of the trial, 29 AEs were reported. A total of 25 were in the eculizumab arm and four in the placebo arm. The two most commonly reported AEs, occurring in either group, were derangements in liver function (rising liver transaminases) and infections. In the five reported cases of liver function derangement, three subjects had mildly deranged transaminases prior to infusion of trial medications. All liver function test derangements had resolved by the end of the trial visits. Of those with an infectious AE, four had lower respiratory tract infections and one had acute cholecystitis.
Four SAEs occurred in the eculizumab cohort and none in the control cohort. Three were deemed as having no causality to the drug intervention and one with possible causality to the drug intervention. Subject E3 had a lower respiratory tract infection preventing administration of trial drug (possible causality), and died at week 21 due to septic shock and multi-organ failure (non-causal). Subject E4 had opioid toxicity requiring high dependency unit admission (non-causal) and resulting in an aspiration pneumonia leading to intensive care unit (ICU) admission (non-causal).
Primary efficacy endpoint
By 4 weeks, two of two placebo-and two of five eculizumab-treated subjects had improved by one or more grades on the GBS DS ( Fig. 2A, Table 4 ).
Secondary Outcome Measurements Time to improvement of one GBS DS point
Of the five who received eculizumab, three (E1, E2, E5, 60%) achieved an improvement of one GBS DS grade over the duration of the trial (Fig. 2A) . This was achieved by week 2 (E1), week 3 (E2), and week 13 (E5). The placebo-treated subjects achieved improvements of one GBS DS grade by week 1 (P1) and week 2 (P2) (Table 4, Fig. 2) .
One of five eculizumab-treated subjects (E2) and one of the two placebo-treated subjects (P1) achieved a GBS DS score of 2 or less (independently walking) by week 8 of the trial. By week 13, one further eculizumab-treated patient (E1) and one further placebo-treated patient had also reached this outcome. Three of five eculizumab-treated subjects failed to achieve independent walking (GBS DS 2) by 6 months. One eculizumab-treated patient (E3) died of sepsis whilst still being ventilated at week 21. During the period prior to his death, motor function had been improving, as reflected in other scoring scales (E3 data from week 13 is displayed).
Rasch-built overall disability score
At week 4, two of five (40%) eculizumab-treated subjects (E1 and E2) had an increase of at least 6 Figure 1 . Recruitment log for screened subjects. Solid line denotes total Guillain-Barré syndrome (GBS) subjects at Hughes GBS disability score (GBS DS) grade 3 or greater undergoing screening for inclusion (28); dotted line denotes subjects excluded or who declined to participate (20); dashed line denotes subjects recruited into the study (8). The recruitment target was 30 subjects over 2 years. Of the 20 subjects who were excluded, 12 declined to participate, and 8 were excluded for failing to meet other inclusion criteria. points on the R-ODS (with an 11 point and a 38 point improvement, respectively), whilst one further patient (E5) had an improvement of 5 points (Fig. 2B) . Both of the remaining subjects were very severely affected. One remained static with an R-ODS score of 0 (E3) and one deteriorated by 11 points (falling from 11 to 0; E4). Both placebo-treated subjects had achieved at least 6 point improvement at week 4, having improved by 41 (E1) and 15 (E2) points. At week 26, four of five eculizumab-treated subjects had improved by at least 6 points (range from 16 to 74 points), as had both placebo-treated subjects, achieving a 94 point (P1) and 64 point (P2) improvement.
MRC sum score
At week 4, two eculizumab-treated subjects (E3 and E4) had regressed in their MRC SS (Fig. 2C) . All other subjects (three treated and two placebo) improved by at least one point. At week 26, four eculizumab-treated patients had improved to near normal (range 54-59). At week 13, the MRC SS of E3 was 26. At 26 weeks, the two placebo-treated subjects had recovered (P1, 60; P2, 58).
Overall neuropathy limitation score
Of the five eculizumab-treated subjects, two subjects (E1 and E2) had an improvement of at least 1 point (3-and 8-point improvement, respectively) at 4 weeks (Fig. 2D) . Four eculizumab-treated subjects had an improvement of at least 1 point by week 26 (range from 1 to 10 points). Patient E3 had improved by 1 point at week 13, and died at week 21. Both placebo subjects had improved by 1 point at week 4, with an overall improvement of 7 (P1) and 10 (P2) ONLS points by trial completion.
Ventilation requirements and ICU admissions
Three eculizumab-treated subjects required ICU admission, with two eculizumab-treated subjects (E3 and E4) requiring mechanical ventilation (Table 4) . Subject E3 had a progressive bulbar palsy and was electively intubated for airway protection before receiving eculizumab doses, and subject E4 required mechanical ventilation due to pneumonia and sepsis during weeks 2 and 3 of their admission after starting eculizumab doses. Patient E3 was ventilator dependent throughout the trial. Patient 4 was ventilated for 10 days, although due to bulbar weakness retained a tracheostomy for 5 months. Patient E2 required high dependency care with high flow oxygen and non-invasive ventilation for 5 days, but did not require invasive mechanical ventilation. Neither placebo-treated subjects required ICU level care. Two eculizumab-treated subjects required inotropic support for unstable blood pressure. Patient E3 had a combination of autonomic dysfunction secondary to GBS and sepsis, and required inotropic support for 6 weeks. Patient E4 had sepsis-related hypotension and required inotropic support for 4 days. Neither placebo-treated patient required cardiovascular support.
Observed vs. predicted outcome
The modified Erasmus GBS Outcome Score (mEGOS) scale (Appendix 3E in the Supporting Information) was used to estimate predicted outcomes in all subjects. This was compared with observed outcome (Table 5 ). Whilst these comparative data are only probabilistic, subjects E4 and E5 appeared to underperform as manifested by the inability to walk independently at week 26 despite an 85% (E4) and 93% (E5) probability of being able to do so, as defined by their mEGOS score. Excepting case E3 who died, other subjects conformed to their predicted probabilities by week 26 or earlier.
The modified Erasmus GBS Respiratory Insufficiency Score (mEGRIS) scale (Appendix 3F in the Supporting Information) was used to predict requirement of mechanical ventilation in the first week of illness. This was compared with observed outcome. One Probability of walking independently (%; GBS DS ≤ 2), based on modified Erasmus GBS Outcome Score (mEGOS) classifications at weeks 4, 13, and 26, vs. observed walking status. Walking is defined as GBS DS 2 or less. E1-E5, eculizumab-treated subjects; Obs., observed; P1 and P2 placebo-treated subjects; Pred., predicted; GBS DS, Guillain-Barré syndrome disability score.
patient (E3) was predicted high risk (mEGRIS = 5) and required ventilation at day 5 of his illness.
Discussion
This phase 2 study was designed to assess the safety and tolerability of eculizumab administration concomitantly with IVIg in subjects with severe GBS (GBS DS 3 or greater). These data show that the combination therapy was safe and well-tolerated. The most common AEs reported were infection and deterioration in liver function, both of which are recognised complications of eculizumab administration but are also common complications of GBS (Oomes et al., 1996) . Administering the full doses of eculizumab was prevented in two subjects due to sepsis, as outlined in the study protocol. This may pose a problem in severely affected subjects with GBS, as they are at a high risk for ventilator acquired pneumonia, aspiration due to bulbar weakness, and urinary tract sepsis due to indwelling urinary catheters. The effect of missed drug doses on attenuating systemic complement inhibition also needs to be considered, although this was not formally evaluated through serum complement activity measurement in this study. The infusions themselves were well-tolerated, with only one reported rash. The concomitant ciprofloxacin was also well-tolerated and meningitis was not seen. The single fatality, occurring in an eculizumab-treated patient, was deemed to be unrelated to the study drug as it occurred in week 21, over 18 weeks after its last administration and well beyond its functional half-life.
Recruitment into the trial was unexpectedly difficult. Many participants declined, despite being eligible on other grounds. Overwhelmingly, the perceived risk and fear of meningitis, a known complication of eculizumab discussed during informed consent, was the critical element in participants declining. Whether the excluded subjects introduced a selection bias is not known as their outcomes are unknown; nevertheless this factor should be considered.
The small sample size means the efficacy results are not amenable to statistical analysis. No clear trends in efficacy were apparent but this is not unexpected in such a small sample size. Similarly, a small study is potentially vulnerable to differences in baseline characteristics that cannot be balanced in a controlled way. Larger studies would be required for such analysis. The overall course in these severely affected GBS subjects did not seem out of the ordinary, varying in range from full recovery to death. Neurophysiological studies and anti-ganglioside antibody analysis revealed a mixed cohort, with some showing markers typical for axonal GBS, and others not (Goodfellow and Willison, 2016) .
This study concludes that eculizumab appears well-tolerated in acute GBS subjects and can be given safely in conjunction with IVIg. Although it is tempting to speculate on the varied clinical outcome following eculizumab in this group of patients, the small sample size precludes a meaningful assessment of efficacy. Efficacy data from another ongoing Japanese phase 2 study of similar design (Japanese Eculizumab Trial for GBS JET-GBS, ClinicalTrials.gov NCT02493725) are awaited with interest. The study also illustrates the challenges of testing novel immunotherapies in GBS subjects with sepsis. Difficulties in recruitment and ongoing drug administration were encountered, principally due to infection considerations related to both perceived risks of study drug and their frequent occurrence in GBS. These issues need to be carefully considered when designing future studies if a recruitment rate of under 30% of eligible subjects is estimated for phase 3 trials, study populations need to be at 3-4 times the recruitment target. Advances in treatment of GBS are urgently required, universally adopted, and adaptively designed trial protocols for assessing new pathway-specific immunotherapies that do not depend upon large randomised control trials would be advantageous for accelerating progress.
